Inconsistent findings are reported on whether insulin-like growth factor-1 (IGF-1) is protective or harmful in predicting hypertension, carotid wall thickness and mortality. We determined the five-year prognostic value of IGF-1 for these outcomes in a large Black population prone to hypertension and cardiovascular disease.
Design
A longitudinal study as part of the PURE (Prospective Urban and Rural Epidemiology) study, North West Province, South Africa.
Methods
We measured IGF-1 and IGF binding protein-3 (IGFBP-3) in 1038 HIV-uninfected participants (age range 32–94 years) and assessed blood pressure, carotid intima-media thickness and mortality.
Results
Over five years 116 deaths occurred. Baseline IGF-1 was similar in survivors and non-survivors (p = 0.50), but tended to be higher in survivors upon adjustment for IGFBP-3 and covariates (p = 0.061). Normotensives and hypertensives (p = 0.072), and those with carotid intima-media thickness < 0.9 mm and ≥ 0.9 mm also displayed similar baseline IGF-1 (p = 0.55). Multivariable-adjusted Cox-regression indicated high IGF-1 predicting lower risk for all-cause mortality (hazard ratio 0.45; 0.23–0.88) and cardiovascular mortality (hazard ratio 0.26; 0.08–0.83) when also adjusting for IGFBP-3. When including normo- and hypertensives at baseline, high IGF-1 was related to normotension at follow-up (hazard ratio 0.68; 0.49–0.95). We found no association with carotid intima-media thickness (hazard ratio 0.59; 0.31–1.14).
Conclusion
In a Black South African population with low socio-economic status and harmful health behaviours, we found a protective independent association between IGF-1 and hypertension, cardiovascular and all-cause mortality, with no association with carotid wall thickness.
DiezJLaviadesC. Insulin-like growth factor I and collagen type III synthesis in patients with essential hypertension and left ventricular hypertrophy. J Hum Hypertens1994; 8(Suppl. 1): S21–S25.
2.
LaviadesCGilMJMonrealI. Is the tissue availability of circulating insulin-like growth factor I involved in organ damage and glucose regulation in hypertension?J Hypertens1997; 15: 1159–1165.
3.
ZachariahJPXanthakisVLarsonMG. Circulating vascular growth factors and central hemodynamic load in the community. Hypertension2012; 59: 773–779.
4.
SchutteAEVolpeMTocciG. Revisiting the relationship between blood pressure and insulin-like growth factor-1. Hypertension2014; 63: 1070–1077.
5.
FischerFSchulteHMohanS. Associations of insulin-like growth factors, insulin-like growth factor binding proteins and acid-labile subunit with coronary heart disease. Clin Endocrinol (Oxf)2004; 61: 595–602.
6.
SchutteAESchutteRSmithW. Compromised bioavailable IGF-1 of black men relates favourably to ambulatory blood pressure: The SABPA study. Atherosclerosis2014; 233: 139–144.
7.
KawachiSTakedaNSasakiA. Circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 are associated with early carotid atherosclerosis. Arterioscler Thromb Vasc Biol2005; 25: 617–621.
8.
MartinRMGunnellDWhitleyE. Associations of insulin-like growth factor (IGF)-I, IGF-II, IGF binding protein (IGFBP)-2 and IGFBP-3 with ultrasound measures of atherosclerosis and plaque stability in an older adult population. J Clin Endocrinol Metab2008; 93: 1331–1338.
9.
SukhanovSHigashiYShaiSY. Differential requirement for nitric oxide in IGF-1-induced anti-apoptotic, anti-oxidant and anti-atherosclerotic effects. FEBS Lett2011; 585: 3065–3072.
10.
WangJRazuvaevAFolkersenL. The expression of IGFs and IGF binding proteins in human carotid atherosclerosis, and the possible role of IGF binding protein-1 in the regulation of smooth muscle cell proliferation. Atherosclerosis2012; 220: 102–109.
11.
BourronOLeBYBerardL. Impact of age-adjusted insulin-like growth factor 1 on major cardiovascular events after acute myocardial infarction: Results from the fast-MI registry. J Clin Endocrinol Metab2015; 100: 1879–1886.
12.
LaughlinGABarrett-ConnorECriquiMH. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: The Rancho Bernardo Study. J Clin Endocrinol Metab2004; 89: 114–120.
13.
AndreassenMRaymondIKistorpC. IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. Eur J Endocrinol2009; 160: 25–31.
14.
KaplanRCMcGinnAPPollakMN. Total insulinlike growth factor 1 and insulinlike growth factor binding protein levels, functional status, and mortality in older adults. J Am Geriatr Soc2008; 56: 652–660.
15.
van BunderenCCvan NieuwpoortICvan SchoorNM. The association of serum insulin-like growth factor-I with mortality, cardiovascular disease, and cancer in the elderly: A population-based study. J Clin Endocrinol Metab2010; 95: 4616–4624.
16.
YeapBBChubbSAMcCaulKA. Associations of IGF1 and IGFBPs 1 and 3 with all-cause and cardiovascular mortality in older men: The Health In Men Study. Eur J Endocrinol2011; 164: 715–723.
17.
BeberashviliISinuaniIAzarA. Decreased IGF-1 levels potentiate association of inflammation with all-cause and cardiovascular mortality in prevalent hemodialysis patients. Growth Horm IGF Res2013; 23: 209–214.
18.
JuulAScheikeTDavidsenM. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: A population-based case-control study. Circulation2002; 106: 939–944.
19.
ContiECarrozzaCCapoluongoE. Insulin-like growth factor-1 as a vascular protective factor. Circulation2004; 110: 2260–2265.
20.
ContiEMusumeciMBDeGM. IGF-1 and atherothrombosis: Relevance to pathophysiology and therapy. Clin Sci (Lond)2011; 120: 377–402.
21.
IzharUHasdaiDRichardsonDM. Insulin and insulin-like growth factor-I cause vasorelaxation in human vessels in vitro. Coron Artery Dis2000; 11: 69–76.
22.
WickmanAJonsdottirIHBergstromG. GH and IGF-I regulate the expression of endothelial nitric oxide synthase (eNOS) in cardiovascular tissues of hypophysectomized female rats. Eur J Endocrinol2002; 147: 523–533.
23.
LeRoithDWernerHBeitner-JohnsonD. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev1995; 16: 143–163.
24.
HiraiHKanayaRMaedaM. The role of insulin growth factor on atherosclerosis and endothelial function: The effect on hyperlipidemia and aging. Life Sci2011; 88: 425–431.
25.
RenehanAGZwahlenMMinderC. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis. Lancet2004; 363: 1346–1353.
26.
SchutteAESchutteRHuismanHW. Are behavioural risk factors to be blamed for the conversion from optimal blood pressure to hypertensive status in Black South Africans? A 5-year prospective study. Int J Epidemiol2012; 41: 1114–1123.
27.
Lloyd-SherlockPBeardJMinicuciN. Hypertension among older adults in low- and middle-income countries: Prevalence, awareness and control. Int J Epidemiol2014; 43: 116–128.
28.
SliwaKWilkinsonDHansenC. Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): A cohort study. Lancet2008; 371: 915–922.
29.
SchamrothC. Management of acute coronary syndrome in South Africa: Insights from the ACCESS (Acute Coronary Events – a Multinational Survey of Current Management Strategies) registry. Cardiovasc J Afr2012; 23: 365–370.
30.
Kakou-GuikahueMN’GuettaRnzouan-KacouJB. Optimizing the management of acute coronary syndromes in sub-Saharan Africa: A statement from the AFRICARDIO 2015 Consensus Team. Arch Cardiovasc Dis2016; 109: 376–383.
31.
SchutteAEHuismanHWvan RooyenJM. A significant decline in IGF-I may predispose young Africans to subsequent cardiometabolic vulnerability. J Clin Endocrinol Metab2010; 95: 2503–2507.
32.
SuccurroEAndreozziFSciaquaA. Reciprocal association of plasma IGF-1 and interleukin-6 levels with cardiometabolic risk factors in nondiabetic subjects. Diabetes Care2008; 31: 1886–1888.
33.
Dall’AglioESalimbeniIRocciA. Modifications of blood pressure and IGF-I levels after weight loss in obesity. J Endocrinol Invest2002; 25: 107–109.
34.
GapsturSMKoppPChiuBC. Longitudinal associations of age, anthropometric and lifestyle factors with serum total insulin-like growth factor-I and IGF binding protein-3 levels in Black and White men: The CARDIA Male Hormone Study. Cancer Epidemiol Biomarkers Prev2004; 13: 2208–2216.
35.
RojdmarkSRydvaldYAquiloniusA. Insulin-like growth factor (IGF)-1 and IGF-binding protein-1 concentrations in serum of normal subjects after alcohol ingestion: Evidence for decreased IGF-1 bioavailability. Clin Endocrinol (Oxf)2000; 52: 313–318.
NindlBCSanttilaMVaaraJ. Circulating IGF-I is associated with fitness and health outcomes in a population of 846 young healthy men. Growth Horm IGF Res2011; 21: 124–128.
38.
TeramukaiSRohanTEguchiH. Anthropometric and behavioral correlates of insulin-like growth factor I and insulin-like growth factor binding protein 3 in middle-aged Japanese men. Am J Epidemiol2002; 156: 344–348.
39.
TeoKChowCKVazM. The Prospective Urban Rural Epidemiology (PURE) study: Examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. Am Heart J2009; 158: 1–7.
40.
ManciaGFagardRNarkiewiczK. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens2013; 31: 1281–1357.
ZatuMCvan RooyenJMLootsdT. Self-reported alcohol intake is a better estimate of 5-year change in blood pressure than biochemical markers in low resource settings: The PURE study. J Hypertens2014; 32: 749–755.
43.
ZatuMCvan RooyenJMKrugerA. Alcohol intake, hypertension development and mortality in black South Africans. Eur J Prev Cardiol2016; 23: 308–315.
44.
WareLJRennieKLKrugerHS. Evaluation of waist-to-height ratio to predict 5 year cardiometabolic risk in sub-Saharan African adults. Nutr Metab Cardiovasc Dis2014; 24: 900–907.
45.
VolzkeHFriedrichNSchipfS. Association between serum insulin-like growth factor-I levels and thyroid disorders in a population-based study. J Clin Endocrinol Metab2007; 92: 4039–4045.
46.
ReddyMAPatelHIKarimSM. Reduced utility of serum IGF-1 levels in predicting retinopathy of prematurity reflects maternal ethnicity. Br J Ophthalmol2016; 100: 501–504.
47.
JuulA. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res2003; 13: 113–170.
48.
ColaoADiSCCascellaT. Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: An observational, exploratory study in 404 subjects. Eur J Endocrinol2008; 159: 389–397.
49.
Landin-WilhelmsenKWilhelmsenLLappasG. Serum insulin-like growth factor I in a random population sample of men and women: Relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol (Oxf)1994; 41: 351–357.
50.
CapoluongoEPitoccoDLulliP. Inverse correlation between serum free IGF-I and IGFBP-3 levels and blood pressure in patients affected with type 1 diabetes. Cytokine2006; 34: 303–311.
51.
VecchioneCColellaSFrattaL. Impaired insulin-like growth factor I vasorelaxant effects in hypertension. Hypertension2001; 37: 1480–1485.
HuYPeteGWalshMF. Central IGF-1 decreases systemic blood pressure and increases blood flow in selective vascular beds. Horm Metab Res1996; 28: 211–214.
54.
Bayes-GenisAConoverCASchwartzRS. The insulin-like growth factor axis: A review of atherosclerosis and restenosis. Circ Res2000; 86: 125–130.
55.
Fernandez-HernandoCAckahEYuJ. Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease. Cell Metab2007; 6: 446–457.
56.
Fernandez-HernandoCJozsefLJenkinsD. Absence of Akt1 reduces vascular smooth muscle cell migration and survival and induces features of plaque vulnerability and cardiac dysfunction during atherosclerosis. Arterioscler Thromb Vasc Biol2009; 29: 2033–2040.
57.
OosthuizenWVorsterHHKrugerA. Impact of urbanisation on serum lipid profiles – the THUSA survey. S Afr Med J2002; 92: 723–728.
58.
SchutteAESchutteRHuismanHW. Classifying Africans with the metabolic syndrome. Horm Metab Res2009; 41: 79–85.
59.
JanssenJAStolkRPPolsHA. Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: Relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol1998; 18: 277–282.
60.
HarrelaMQiaoQKoistinenR. High serum insulin-like growth factor binding protein-1 is associated with increased cardiovascular mortality in elderly men. Horm Metab Res2002; 34: 144–149.
61.
HuDPawlikowskaLKanayaA. Serum insulin-like growth factor-1 binding proteins 1 and 2 and mortality in older adults: The Health, Aging, and Body Composition Study. J Am Geriatr Soc2009; 57: 1213–1218.
62.
SaydahSGraubardBBallard-BarbashR. Insulin-like growth factors and subsequent risk of mortality in the United States. Am J Epidemiol2007; 166: 518–526.
63.
van BunderenCCOosterwerffMMvan SchoorNM. Serum IGF1, metabolic syndrome, and incident cardiovascular disease in older people: A population-based study. Eur J Endocrinol2013; 168: 393–401.
64.
BurgersAMBiermaszNRSchoonesJW. Meta-analysis and dose-response metaregression: Circulating insulin-like growth factor I (IGF-I) and mortality. J Clin Endocrinol Metab2011; 96: 2912–2920.
65.
RoubenoffRPariseHPayetteHA. Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: The Framingham Heart Study. Am J Med2003; 115: 429–435.
66.
BrugtsMPvan den BeldAWHoflandLJ. Low circulating insulin-like growth factor I bioactivity in elderly men is associated with increased mortality. J Clin Endocrinol Metab2008; 93: 2515–2522.
67.
FriedrichNHaringRNauckM. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J Clin Endocrinol Metab2009; 94: 1732–1739.
68.
WatanabeSTamuraTOnoK. Insulin-like growth factor axis (insulin-like growth factor-I/insulin-like growth factor-binding protein-3) as a prognostic predictor of heart failure: Association with adiponectin. Eur J Heart Fail2010; 12: 1214–1222.
69.
ArcopintoMIsgaardJMarraAM. IGF-1 predicts survival in chronic heart failure. Insights from the T.O.S.CA. (Trattamento Ormonale Nello Scompenso CArdiaco) registry. Int J Cardiol2014; 176: 1006–1008.
70.
JiaTGamaATHeimburgerO. IGF-1 and survival in ESRD. Clin J Am Soc Nephrol2014; 9: 120–127.
71.
MilmanSAtzmonGHuffmanDM. Low insulin-like growth factor-1 level predicts survival in humans with exceptional longevity. Aging Cell2014; 13: 769–771.
72.
VitaleGBrugtsMPOgliariG. Low circulating IGF-I bioactivity is associated with human longevity: Findings in centenarians’ offspring. Aging (Albany NY)2012; 4: 580–589.
73.
LaronZ. The GH-IGF1 axis and longevity. The paradigm of IGF1 deficiency. Hormones (Athens)2008; 7: 24–27.
74.
BothaSFourieCMSchutteR. Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population. Int J Cardiol2015; 184: 631–636.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
